Last edition
News about
US-based biotechnology company Kaigene has signed an exclusive global licensing agreement with South Korean biopharmaceutical giant Celltrion to develop and commercialise two of its nonclinical-stage antibody assets, KG006 and KG002.
Merck Foundation Unveils USD 22 Million Programme to Enhance Cardiovascular Care across US
The Merck Foundation has launched a USD 22 million programme to strengthen cardiovascular care across the United States, awarding grants to 11 organisations to develop and implement evidence-based initiatives aimed at improving outcomes in underserved communities facing barriers to timely heart disease care.
Glenmark to Launch 8.4% Sodium Bicarbonate Injection in the US Market
Glenmark Pharmaceuticals has announced its upcoming launch of 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial in the US market.
Alkem and IIT Bombay Collaborate to Launch R and D Centre for Advanced Immunotherapies
Alkem Laboratories, through its CSR arm, has partnered with IIT Bombay to establish the Alkem Centre for Advanced Research and Development of Applied Immuno-Therapeutics & Regenerative Medicines on the institute’s campus.
Eli Lilly to Pour USD 1.2B into Puerto Rico Facility Expansion Amid USA Manufacturing Push
Eli Lilly announced plans to invest more than USD 1.2 billion to expand and modernise its Lilly del Caribe manufacturing site in Carolina, Puerto Rico, as part of its broader initiative to enhance pharmaceutical production in the United States.
Motorica Unveils World's First Bionic Hand Prosthesis with Optical Myography Sensors
Motorica, a global MedTech company specialising in assistive technologies and medical cybernetics, has unveiled Omni Hand, the world’s first bionic hand prosthesis equipped with optical myography (OMG) sensors.
Bharat Biotech Launches Nucelion, a New CRDMO Focused on Cell and Gene Therapies
The new entity, based in Genome Valley, Hyderabad, is designed to partner with global life-science innovators to deliver end-to-end solutions for complex biologic medicines.
Akeso's Ivonescimab Wins 4th Breakthrough Therapy Nod in China for TNBC
Akeso has secured its fourth Breakthrough Therapy Designation (BTD) in China for Ivonescimab, targeting first-line treatment of triple-negative breast cancer (TNBC). The ongoing Phase III HARMONi-BC1 trial is assessing its safety and efficacy in this hard-to-treat cancer type.
GC Biopharma's Anthrax Vaccine Shows Safety and Immunogenicity in Phase 2 trial
The Phase 2 clinical trial demonstrated that the anthrax vaccine by GC Biopharma elicited antibodies that neutralised the anthrax toxin at a level exceeding the pre-defined protective threshold. This finding indicates robust immunogenicity and suggests that BARYTHRAX can provide clinically meaningful protection against anthrax infection.
Lonza to Acquire Redberry, Expanding its Rapid Microbiology Testing Capabilities
Lonza, one of the world’s largest contract development and manufacturing organisations (CDMOs), has signed an agreement to acquire Redberry SAS (Redberry), an innovative company specialising in rapid microbiology testing solutions using solid-phase cytometry (SPC) technology.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy